CytomX Q2 FY26 net loss widens to $20.67 million; revenue drops to $1.42 million

Reuters2026/08/06 20:24

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

CytomX posted Q2 revenue of USD 1.42 million, down 92.4% year over year as collaboration activity eased.
Net loss attributable to common stockholders widened to USD 20.67 million; loss per share was USD 0.09.
Operating loss widened to USD 23.78 million as operating expenses rose to USD 25.2 million, led by RD costs of USD 17.6 million.
Cash, cash equivalents and investments fell to USD 330.3 million at June 30 from USD 346.7 million at March 31; runway forecast into 2H 2028.
Varseta-M Phase 1 monotherapy update in advanced CRC due by end-2026; first registrational CRC study targeted for 1H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

CytomX Q2 FY26 net loss widens to $20.67 million; revenue drops to $1.42 million

You may also like

Crypto prices